- Tipos de Cáncer
Tipos de Cáncer
Información sobre riesgo, prevención, detección, síntomas, diagnosis, tratamiento y apoyo para el cáncer.A a la Z - Tratamiento
Tratamiento del Cáncer
Información sobre el tratamiento del cáncer incluyendo quirúrgica, quimioterapia, radioterapia, estudios clínicos, terapia con protón, medicina complementaria avanzadas.
- Riesgo de concer y prevencion
- Drogas de Cáncer
OncoLink se complace en ofrecer una amplia lista de lista completa de los agentes quimioterapéuticos más comúnmente usados??. Esta guía de referencia incluye información sobre la forma en que cada fármaco se administra, cómo funcionan, y los pacientes los efectos secundarios comunes pueden experimentar.
- Lidiando
Lidiando con el Cáncer
Maneras que los pacientes de cáncer y las personas que le cuidan puedan enfrentar el cáncer, los efectos secundarios, nutrición, cuestiones en general sobre el apoyo para el cáncer, duelo/decisiones sobre el termino de vida, y experiencias compartidas por sobrevivientes.
- Profesionales de la salud
- Estudios Clínicos
Notas para enfermeros 
¿Cuál es mi riesgo? k? 
OncoPilot: Manejando su experiencia del cáncer 
OncoLink Cancer Blogs
Community Events Calendar 
Abramson Cancer Center 
NCI CANCERLIT® Search: AIDS-Related Kaposi's Sarcoma - April 2002
National Cancer Institute®
Ultima Vez Modificado: 1 de abril del 2002
Table of Contents
1
UI - 11779265
AU - Osmond DH; Buchbinder S; Cheng A; Graves A; Vittinghoff E; Cossen CK;
TI -
Forghani B; Martin JN
Prevalence of Kaposi sarcoma-associated herpesvirus infection in
homosexual men at beginning of and during the HIV epidemic.
SO - JAMA 2002 Jan 9;287(2):221-5
AD - Department of Epidemiology and Biostatistics, University of California,
San Francisco, CA 94143, USA. dosmond@psg.ucsf.edu
CONTEXT: Some studies have inferred that an epidemic of Kaposi
sarcoma-associated herpesvirus (KSHV) infection in homosexual men in the
United States occurred concurrently with that of human immunodeficiency
virus (HIV), but there have been no direct measurements of KSHV
prevalence at the beginning of the HIV epidemic. OBJECTIVES: To
determine the prevalence of KSHV infection in homosexual men in San
Francisco, Calif, at the beginning of the HIV epidemic in 1978 and 1979
and to examine changes in prevalence of KSHV at time points from 1978
through 1996 in light of changes in sexual behavior. DESIGN, SETTING,
AND PARTICIPANTS: Analysis of a clinic-based sample (n = 398) derived
from the San Francisco City Clinic Cohort (ages 18-66 years) (n = 2666
for analyses herein) and from population-based samples from the San
Francisco Men's Health Study (MHS) (ages 25-54 years) (n = 825 and 252)
and the San Francisco Young Men's Health Study (YMHS) (ages 18-29 years)
(n = 428-976, and 557); behavioral studies were longitudinal and KSHV
prevalence studies were cross-sectional. MAIN OUTCOME MEASURES:
Antibodies against KSHV and HIV; sexual behaviors. RESULTS: The
prevalence of KSHV infection in 1978 and 1979 was 26.5% of 235 (a random
sample) overall (weighted for HIV infection) vs 6.9% (128/1842) for HIV
in the San Francisco City Clinic Cohort sample. The prevalence of KSHV
infection remained essentially unchanged between an MHS sample of 252 in
1984 and 1985 (29.6%) and a YMHS sample of 557 in 1995 and 1996 (26.4%),
while HIV prevalence dropped from 49.5% of 825 in 1984 and 1985 (MHS) to
17.6% of 428 in 1992 and 1993 (YMHS). The proportion of men practicing
unprotected receptive anal intercourse with 1 or more partners declined
from 54% to 11% during the 1984 through 1993 period (MHS) with similar
though slightly higher values in the YMHS in 1992 and 1993; whereas for
unprotected oral intercourse it ranged between 60% and 90% in the 1984
through 1996 period (MHS and YMHS). CONCLUSIONS: Infection with KSHV was
already highly prevalent in homosexual men when the HIV epidemic began
in San Francisco, and its prevalence has been maintained at a nearly
constant level. Any declines in the incidence of Kaposi sarcoma do not
appear to be caused by a decline in KSHV transmission.
2
UI - 11911748
AU - O'Brien TR; Engels EA; Rosenberg PS; Goedert JJ
TI -
Relationship between Kaposi sarcoma-associated herpesvirus and HIV.
SO - JAMA 2002 Mar 27;287(12):1525-6; discussion 1527-8
3
UI - 11911750
AU - Haverkos HW; Kopstein AN
TI -
Relationship between Kaposi sarcoma-associated herpesvirus and HIV.
SO - JAMA 2002 Mar 27;287(12):1526-8
4
UI - 11911749
AU - Cannon MJ; Pellett PE
TI -
Relationship between Kaposi sarcoma-associated herpesvirus and HIV.
SO - JAMA 2002 Mar 27;287(12):1526; discussion 1527-8
5
UI - 11789020
AU - Saif MW
TI -
Castleman disease in an HIV-infected patient with Kaposi sarcoma.
SO - AIDS Read 2001 Nov;11(11):572-6
AD - Division of Hematology/Oncology, University of Alabama at Birmingham,
Wallace Tumor Institute, USA.
Multicentric Castleman disease (MCD) is a heterogeneous
lymphoproliferative disorder, characterized by systemic symptoms,
generalized lymphadenopathy, hepatosplenomegaly, proteinuria, and rash.
The clinical course is variable and may range from indolent to
aggressive, fulminating in a rapidly fatal illness. Mortality is usually
from infective complications and less commonly from malignancies, such
as lymphoma or Kaposi sarcoma. The association of concurrent or
preceding Castleman disease with Kaposi sarcoma is well documented.
Castleman disease developed in a 51-year-old patient with AIDS about 10
months after diagnosis of Kaposi sarcoma. MCD was found to be associated
with human herpesvirus 8/Kaposi sarcoma-associated herpesvirus.
6
UI - 11730058
AU - Atillasoy ES; Santoro A; Weinberg JM
TI -
Lymphoedema associated with Kaposi's sarcoma.
SO - J Eur Acad Dermatol Venereol 2001 Jul;15(4):364-5
7
UI - 9815666
AU - Husain SR; Obiri NI; Gill P; Zheng T; Pastan I; Debinski W; Puri RK
TI -
Receptor for interleukin 13 on AIDS-associated Kaposi's sarcoma cells
serves as a new target for a potent Pseudomonas exotoxin-based chimeric
toxin protein.
SO - Clin Cancer Res 1997 Feb;3(2):151-6
AD - Laboratory of Molecular Tumor Biology, Division of Cellular and Gene
Therapies, Center for Biologics Evaluation and Research, Food and Drug
Administration, Bethesda, Maryland 20892, USA.
AIDS-associated Kaposi's sarcoma (AIDS-KS), the most common malignant
complication of human immunodeficiency virus infection, is characterized
by neoplastic proliferation of mesenchymal cells. AIDS-KS cells release
and respond to an array of cytokines through specific plasma membrane
receptors. Specific targeting of potent cytotoxic agents to cell surface
receptors/antigens on Kaposi's sarcoma cells may provide effective
therapy for this malignancy. We have identified a new target in the form
of an interleukin 13 (IL-13) receptor that is overexpressed in the five
AIDS-KS cell lines examined. Radiolabeled IL-13 cross-linked to a single
protein of about Mr 70,000 in AIDS-KS cells. We utilized a chimeric
cytotoxic protein composed of IL-13 and a truncated Pseudomonas exotoxin
(IL13-PE38QQR), which was found to be specifically and highly cytotoxic
to AIDS-KS cells, as determined by protein synthesis inhibition and
clonogenic assays. IL13-PE38QQR demonstrated significant antitumor
activity in a human epidermoid carcinoma xenograft model. Normal human
umbilical vein-derived endothelial, lymphoid, and bone marrow precursor
cells expressed low levels of IL-13 receptors, and IL-13 toxin was not
cytotoxic to them. Thus, IL-13 receptor on AIDS-KS cells may represent a
novel plasma membrane protein(s) that could be utilized to target
therapeutic agents.
8
UI - 10673512
AU - Tulpule A; Scadden DT; Espina BM; Cabriales S; Howard W; Shea K; Gill PS
TI -
Results of a randomized study of IM862 nasal solution in the treatment
of AIDS-related Kaposi's sarcoma.
SO - J Clin Oncol 2000 Feb;18(4):716-23
AD - Department of Medicine, Division of Hematology, Kenneth Norris Cancer
Hospital and Research Institute, University of Southern California
School of Medicine, Los Angeles, CA, USA.
PURPOSE: Although advances have been made in the treatment of
AIDS-related Kaposi's sarcoma (AIDS-KS) with systemic chemotherapy, less
toxic therapies are needed. IM862 is a naturally occurring peptide with
antiangiogenic properties and was thus studied in patients with AIDS-KS.
PATIENTS AND METHODS: IM862 was given as intranasal drops at a dose of 5
mg. Patients were randomized to two dosing schedules given in repeated
cycles until disease progression or unacceptable toxicity: 5 days of
therapy followed by 5 days off (n = 18) and every other day dosing (n =
26). RESULTS: Forty-two male patients and two female patients with a
median age of 38 years (range, 22 to 53 years) were accrued. Twenty-one
patients (47%) had more than 50 mucocutaneous lesions, 14 (32%) had
lymphedema, and none had visceral involvement. Thirty-three patients
(75%) had received prior systemic chemotherapy. Twenty-four patients
(55%) had CD4(+) lymphocyte count 9
UI - 11215084
AU - Anonymous
TI -
AIDS-related Kaposi sarcoma trial is under way.
SO - AIDS Read 2001 Jan;11(1):28
10
UI - 11827836
AU - Plettenberg A; Albrecht D; Lorenzen T; Meyer T; Arndt R; Stoehr A
TI -
Monitoring of endogenous interferon-alpha and human herpesvirus 8 in
HIV-infected patients with Kaposi's sarcoma.
SO - Eur J Med Res 2002 Jan 29;7(1):19-24
AD - Institute for interdisciplinary infectiology and immunology GmbH,
General Hospital St. Georg, Lohmuhlenstr. 5, D-20099 Hamburg, Germany.
plettenberg@ifi-infektiologie.de
The incidence of AIDS-associated Kaposi's sarcoma has declined since the
mid-nineties due to the availability of potent antiretroviral therapy
including protease inhibitors. However, Kaposi's sarcoma is still the
most common neoplasia in HIV-infected patients. In the pathogenesis of
the HIV-associated as well as other forms of this disease an infectious
agent seems to play a role, namely the human herpesvirus 8. Even before
the discovery of the HIV virus, high levels of an unusual acid-labile
form of endogenous interferon alpha were found in patients with
AIDS-associated KS. The administration of recombinant interferon alpha
evolved as standard therapy for Kaposi's sarcoma in HIV-infected
patients with a moderate immunodeficiency in addition to antiretroviral
therapy. This investigation monitored the levels of HHV 8 and endogenous
interferon in 4 patients with and without Kaposi's sarcoma during the
course of HIV-disease. The results of our experiments lead us to two
hypotheses: First of all, the pre-therapeutic level of endogenous
interferon may be a predictor of the response to an interferon-alpha
therapy for HIV-associated Kaposi's sarcoma. Secondly, the determination
of HHV 8 DNA in blood of HIV-positive patients may allow conclusions
about the risk for the development of Kaposi's sarcoma. However these
hypotheses should be tested by monitoring the levels of endogenous
interferon and HHV 8 DNA in clinical studies of a greater number of
HIV-infected patients.
11
UI - 11961149
AU - Webster-Cyriaque J
TI -
Development of Kaposi's sarcoma in a surgical wound.
SO - N Engl J Med 2002 Apr 18;346(16):1207-10
AD - School of Dentistry, University of North Carolina at Chapel Hill, Chapel
Hill 27599-7455, USA. jennifer@med.unc.edu
12
UI - 11948473
AU - Tam HK; Zhang ZF; Jacobson LP; Margolick JB; Chmiel JS; Rinaldo C;
TI -
Detels R
Effect of highly active antiretroviral therapy on survival among
HIV-infected men with Kaposi sarcoma or non-Hodgkin lymphoma.
SO - Int J Cancer 2002 Apr 20;98(6):916-22
AD - School of Public Health, University of California, Los Angeles, CA
90095-1772, USA.
The effect of highly active antiretroviral therapy (HAART) on survival
in HIV-infected patients with Kaposi sarcoma (KS) or non-Hodgkin
lymphoma (NHL) is unknown. Our study examines survival after HAART for
these 2 malignancies. Analyses were performed using data from 387
HIV-infected men in the Multicenter AIDS Cohort Study (MACS) after a
diagnosis of either KS or NHL in 1990-99. Potential prognostic factors,
including HAART, were evaluated in univariate analyses using
Kaplan-Meier survival curves and log-rank tests. Multivariate survival
analyses were conducted using Cox's time-dependent proportional hazards
models, adjusting for CD4(+) cell levels at the time of cancer diagnosis
and other covariates. Forty-three of 287 KS patients (15%) and 13 of 100
NHL patients (13%) had been treated with HAART. HAART treatment was
associated with improved survival for KS and NHL patients (log-rank p =
0.0001 for each group). In multivariate analyses, HAART was associated
with an 81% reduced risk of death among KS patients [relative hazard
(RH) 0.19, 95% confidence limits (CL) (0.08, 0.45)], compared to those
not exposed to HAART and an 84% reduced risk [RH 0.16, 95% CL (0.04,
0.64)] among NHL patients. Relative hazards estimates were similar for
those with HAART initiation before and after NHL diagnosis. The use of
HAART prolongs overall survival among HIV-positive men diagnosed with KS
and NHL. HAART appears to be effective in improving survival even when
initiated after the diagnosis of NHL and KS. Copyright 2002 Wiley-Liss,
Inc.
13
UI - 11895764
AU - Oksenhendler E; Boulanger E; Galicier L; Du MQ; Dupin N; Diss TC;
TI -
Hamoudi R; Daniel MT; Agbalika F; Boshoff C; Clauvel JP; Isaacson PG;
Meignin V
High incidence of Kaposi sarcoma-associated herpesvirus-related
non-Hodgkin lymphoma in patients with HIV infection and multicentric
Castleman disease.
SO - Blood 2002 Apr 1;99(7):2331-6
AD - Department of Immunology and Hematology, Laboratory of Hematology,
Hopital Saint-Louis, 1 Ave Claude Vellefaux, 75010 Paris, France.
eric.oksenhendler@sls.ap-hop-paris.fr
Multicentric Castleman disease (MCD) is a distinct type of
lymphoproliferative disorder associated with inflammatory symptoms and
interleukin 6 (IL-6) dysregulation. In the context of human
immunodeficiency virus (HIV) infection, MCD is associated with Kaposi
sarcoma-associated herpesvirus, also called human herpesvirus type 8
(KSHV/HHV8). Within a prospective cohort study on 60 HIV-infected
patients with MCD, and a median follow-up period of 20 months, 14
patients developed KSHV/HHV8-associated non-Hodgkin lymphoma (NHL): 3
"classic" KSHV/HHV8(+) Epstein-Barr virus-positive (EBV(+)) primary
effusion lymphoma (PEL), 5 KSHV/HHV8(+) EBV(-) visceral large cell NHL
with a PEL-like phenotype, and 6 plasmablastic lymphoma/leukemia (3/3
KSHV/HHV8(+) EBV(-)). The NHL incidence observed in this cohort study
(101/1000 patient-years) is about 15-fold what is expected in the
general HIV(+) population. MCD-associated KSHV/HHV8(+) NHL fell into 2
groups, suggesting different pathogenesis. The plasmablastic NHL likely
represents the expansion of plasmablastic microlymphoma from the MCD
lesion and progression toward aggressive NHL. In contrast, the PEL and
PEL-like NHL may implicate a different original infected cell whose
growth is promoted by the cytokine-rich environment of the MCD lesions.
The above citations and abstracts reflect those newly added to CANCERLIT for the month and topic listed in the title. The citations have been retrieved from CANCERLIT using a predefined search strategy of indexed subject terms. Although the search strategy has been refined as best as possible, citations may appear that are not directly related to the topic, and occasionally relevant references may be omitted.
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
